From the clinic to the capital markets, here is Psychedelic Invest's roundup of the key headlines for the week of June 8–14, 2026.
Optimi Health Corp. (OPTH): Optimi Health secures naturally derived ibogaine to expand its psychedelic drug portfolio
Optimi Health announced it had secured naturally derived ibogaine, in both hydrochloride and freebase forms, from two sources, with development of a finished drug product expected to begin in summer at its GMP facility in British Columbia. The move positions Optimi to supply ibogaine as U.S. federal and Texas-led interest in ibogaine research grows. It extends the company's portfolio beyond psilocybin and MDMA into one of 2026's most closely watched psychedelic compounds.
Source: sec.gov
Optimi Health Corp. (OPTH): Optimi Health completes first psilocybin export to the United Kingdom for a Phase 2 trial
Optimi Health shipped its first batch of naturally derived psilocybin, comprising biomass and finished 5mg capsules, from its Princeton, British Columbia facility to the United Kingdom to supply a planned Phase 2 clinical trial. The export moved under Health Canada export and UK Home Office import authorizations, and the capsules use the same formulation already prescribed in Australia. The shipment demonstrates Optimi's cross-border regulated supply capability, with the trial partner and indication to be disclosed later.
Source: globenewswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.